ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients

Cui, Shengjin; Feng, Jingying; Tang, Xi; Lou, Shuang; Guo, Weiquan; Xiao, Xiaowei; Li, Shuping; Chen, Xue; Huan, Yu; Zhou, Yiwen*; Xiao, Lijia*南方医科大学
EUROPEAN JOURNAL OF MEDICAL RESEARCH2023-2-20DOI: 10.1186/s40001-023-01058-x
1被引5阅读
引用收藏
分享

摘要

ObjectiveAlthough the tumor mutation burden (TMB) was reported as a biomarker for immunotherapy of various cancers, whether it can effectively predict the survival prognosis in breast cancer patients remains unclear. In this study, the prognostic value of TMB and its correlation with immune infiltration were explored by using multigroup studies.MethodsThe somatic mutation data of 986 breast cancer patients were obtained from TCGA database. Breast cancer patients were divided into a low-TMB group and a high-TMB group according to the quartile of TMB scores. The differentially expressed genes (DEGs) were identified by the "limma" R program. The CIBERSORT algorithm was utilized to estimate the immune cell fraction of each sample. The TIMER database was utilized to evaluate the association between CNVs of immune genes and tumor immune cell infiltration and the prognostic value of the immune cells in breast cancer.ResultsIn breast cancer, TP53, PIK3CA, TTN, CDH1 and other genes were the most important mutated genes. Higher survival rate of patients was found in the low-TMB group. Among the top 10 DEGs, three of them belong to the KRT gene family. GSEA enrichment analysis showed that MAPK, Hedgehog, mTOR, TGF-bate and GnRH signaling pathways were enriched in the low-TMB group. The infiltration levels of the most of immune cells were higher in the low-TMB group (P < 0.01). Higher expression of CCL18 and TRGC1 was correlated with poor prognosis. Breast cancer patients with CCL18 copy number variations, especially arm-level gains, showed significantly decreased immune cell infiltration. In the low B cell infiltration group, the survival prognosis of breast cancer patients was poor.ConclusionsTMB is a potential prognosis marker in breast cancer. Immune-related gene CCL18 and TRGC1 are biomarkers of poor prognosis while immune (B cell) infiltration is a biomarker of good prognosis.

学科与关键词

关键词
Breast cancerTumor mutation burden (TMB)Immune infiltrateSurvival
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
EUROPEAN JOURNAL OF MEDICAL RESEARCH
发表日期
2023-02-20
卷期
第 28 卷, 第 1 期
页码
90
DOI
10.1186/s40001-023-01058-x
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81974457]; Natural Science Foundation of Guangdong province, China [2019A1515012079]; Basic Medical and Health Research Project of Baoan District [2020JD428]

作者

  • C

    Cui, Shengjin (第一作者)

    southern med univ

  • F

    Feng, Jingying

    southern med univ

查看全部 11 位作者收起作者
  • T

    Tang, Xi

    southern med univ

  • L

    Lou, Shuang

    southern med univ

  • G

    Guo, Weiquan

    southern med univ

  • X

    Xiao, Xiaowei

    southern med univ

  • L

    Li, Shuping

    southern med univ

  • C

    Chen, Xue

    southern med univ

  • H

    Huan, Yu

    southern med univ

  • Z

    Zhou, Yiwen (通讯)

    southern med univ

  • X

    Xiao, Lijia (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417